RNF181与Hippo/YAP对脑胶质瘤SHG44细胞恶性程度的影响及其可能机制

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1034 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the effect of overexpression of RNF181 on the malignancy of human glioma SHG44 cells and the possible mechanism. Methods Human glioma cell line SHG44 was cultured in vitro. The adenovirus expression vector was transfected to overexpress RNF181. The effects of overexpression of RNF181 on the growth and proliferation of tumor cells, cell stemness, invasion and metastasis in vitro were compared. The expressions of RNF181 and hippo / Yap were detected by Western blot, and the relationship between RNF181 and hippo / Yap was clarified. Finally, the expressions of RNF181 and Yap in SHG44 cells were analyzed by immunofluorescence co-localization. Results After transfection, the relative expression levels of RNF181 mRNA and protein in SHG44 were [(1.95±0.06) and (0.39±0.06)], which were much higher than those of the control group [(1.05±0.03) and (0.23±0.06) ] and the negative group[ (1.03±0.04) and (0.24±0.07)], and the difference was statistically significant (P<0.05). The relative expression levels of YAP mRNA and protein were (1.02±0.04), and (0.29±0.05) in the control group, compared with[(1.03±0.05) and (0.31±0.07)] in the negative group, and [(2.63±0.12) and (0.71±0.06)]in the overexpression group, so the difference was statistically significant (P<0.05). MTT, immunofluorescence and Transwell assay confirmed that the proliferation rate of the RNF181 overexpression group was significantly higher than that of the control group and the negative group. The cell number of the RNF181 overexpression group was significantly larger than that of control group and negative group, so was the number of SHG-44 transmembrane cells. Immunofluorescence co-localization showed that RNF181 and YAP were co-expressed in the nucleus of SHG44. Conclusions Overexpression of RNF181 may contribute to the proliferation and invasion of glioma cells along the Hippo/Yap signaling pathway.

Key words： glioma cells RING finger protein 181 Hippo/Yap malignancy

Received: 20 December 2020

ZTFLH:

R651.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	PEI Meijuan
	SUN Zhonglei
	HUANG Shengxuan
	LIU Yingfu
	LI Xuewen

Cite this article:

PEI Meijuan,SUN Zhonglei,HUANG Shengxuan等. RNF181 promotes malignancy of glioma cells along Hippo / Yap signaling pathway[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2021, 32(7): 553-556.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2021/V32/I7/553

[1]	Bush N A, Chang S M, Berger M S. Current and future strategies for treatment of glioma[J]. Neurosurg Rev, 2017,40(1):1-14.
[2]	武卫周, 钟士江, 王莉. 脑胶质瘤移植模型的研究进展[J].武警医学,2019,30(3):253-256.
[3]	Ouyang T, Meng W, Li M, et al. Recent advances of the hippo/YAP signaling pathway in brain development and glioma[J]. Cell Mol Neurobiol, 2020,40(4):495-510.
[4]	Wang L, Zhang Z, Yu X, et al. Unbalanced YAP-SOX9 circuit drives stemness and malignant progression in esophageal squamous cell carcinoma[J]. Oncogene,2019,38(12):2042-2055.
[5]	Zhou R, Ding Y, Xue M, et al. RNF181 modulates hippo signaling and triple negative breast cancer progression[J]. Cancer Cell Int,2020,20:291.
[6]	Pedersen S M, Chan W, Jattani R P, et al. Negative regulation of CARD11 signaling and lymphoma cell survival by the E3 ubiquitin ligase RNF181[J]. Mol Cell Biol, 2015,36(5):794-808.
[7]	Knudsen K M, Moen G, Fluge O, et al. Pseudoprogression in high-grade glioma[J]. Acta Neurol Scand Suppl, 2013(196):31-37.
[8]	Wang Y, Pan P, Wang Z, et al. β-catenin-mediated YAP signaling promotes human glioma growth[J]. J Exp Clin Cancer Res, 2017,36(1):136.
[9]	Ouyang T, Meng W, Li M, et al. Recent advances of the hippo/YAP signaling pathway in brain development and glioma[J]. Cell Mol Neurobiol,2020,40(4):495-510.
[10]	Kim M H, Kim J. Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies[J]. Cell Mol Life Sci,2017,74(8):1457-1474.
[11]	Thompson B J.YAP/TAZ:drivers of tumor growth,metastasis,and resistance to therapy[J].Bioessays,2020,42(5):e1900162.
[12]	Nguyen C D, Yi C. YAP/TAZ signaling and resistance to cancer therapy[J]. Trends Cancer, 2019,5(5):283-296.
[13]	Yang Y K, Yang C, Chan W, et al. Molecular determinants of scaffold-induced linear ubiquitinylation of B cell lymphoma/leukemia 10 (Bcl10) during T cell receptor and oncogenic caspase recruitment domain-containing protein 11 (CARD11) signaling[J]. J Biol Chem,2016,291(50):25921-25936.
[14]	Gupta A, Jain R, Wahi D, et al. Abrogation of auroraA-TPX2 by novel natural inhibitors: molecular dynamics-based mechanistic analysis[J]. J Recept Signal Transduct Res, 2015,35(6):626-33.

[1]	. [J]. Med. J. Chin. Peop. Armed Poli. Forc., 2021, 32(5): 437-438.